



m4937n

PLACED *PK*

Food and Drug Administration
Minneapolis District
240 Hennepin Avenue
Minneapolis MN 55401-1999
Telephone: 612-334-4100

December 5, 2000

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Refer to MIN 01 - 15

Arif Altaf
Administrator
Pilot City Health Center
1349 Penn Avenue North
Minneapolis, Minnesota 55411

Dear Mr. Altaf:

On November 28, 2000, a representative of the State of Minnesota, acting on behalf of the Food and Drug Administration (FDA), inspected your facility (FDA certificate #187757). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992 (MQSA), your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. Based on the documentation your site presented at the time of the inspection, the following Repeat Level 2 and Level 2 Non-Compliances were documented at your facility:

Repeat Level 2 Non-Compliances:

1. Film processor QC records were missing for three consecutive days (*W* processor, Room 356—Darkrm).
2. Film processor QC records were missing three out of 21 days (14%) of operation in December 1999 (*W* processor, Room 356—Darkrm).
3. Corrective action before further exams, for a failing image score or a phantom background optical density or density difference outside the allowable regulatory limits, was not documented for your mammography system *W* located in Room 354.

Page Two

Arif Altaf
December 5, 2000

Level 2 Non-Compliances:

4. Phantom QC records were missing for at least two weeks but less than four weeks for your mammography system (~~~~~) located in Room 354.
5. Phantom QC is not adequate for your mammography system (~~~~~) located in Room 354 because the image was not taken at the clinical setting.
6. Three of five randomly reviewed mammography reports did not contain an approved "assessment category."

The specific problems noted above appeared on your MQSA Facility Inspection Report which was issued to your facility following the close of the inspection.

Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within 15 working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures if the findings relate to quality control or other records.

Please submit your response to Thomas W. Garvin, Radiological Health Specialist, Food and Drug Administration, 2675 N. Mayfair Road, Suite 200, Milwaukee, WI 53226-1305.

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does


Page Three

Arif Altaf
December 5, 2000

not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov/cdrh/mammography/index.html>.

If you have specific questions about mammography facility requirements or about the content of this letter please feel free to phone Mr. Garvin at (414) 771-7167 ext. 12.

Sincerely,



James A. Rahto
Director
Minneapolis District

TWG/ccl

87

xc:


Lead Interpreting Radiologist
Pilot City Health Center
1349 Penn Ave. No.
Minneapolis, MN 55411

Sue McClanahan
Supervisor, Section of Radiation Control
Minnesota Department of Health
P.O. Box 64975
St. Paul, MN 55164-0975

Priscilla F. Butler
Director, Breast Imaging Accreditation Programs
American College of Radiology
1891 Preston White Drive
Reston, VA 20191